The efficacy of augmented reality exposure therapy in the treatment of spider phobia-a randomized controlled trial.

The evidence for the use of Augmented Reality (AR) in treating specific phobias has been growing. However, issues of accessibility persist, especially in developing countries. The current study examined a novel, but relatively simple therapist guided smartphone-based AR Exposure Treatment (ARET) of spider phobia.

[EPIDEMIOLOGIC SITUATION BY NATURAL-FOCI INFECTIONS IN THE CRIMEA FEDERAL DISTRICT IN 2014-2015].

Aim: Analysis of epidemic manifestations of natural-foci infections (NFI), clarification of spectrum of their causative agents, determination of epizootic activity of natural foci in the Crimea Federal District (KFD).

Materials And Methods: Epizootologic examination of 10 administrative districts of KDF was carried out. 291 pools (2705 specimens) of ixodes ticks and 283 samples of organs of small mammals were studied by PCRmethod for the presence of DNA/RNA of causative agents of a number of NFI.

[The effect of the in-vitro interaction of antibacterial preparations on Brucella melitensis].

The character of drug interaction in 18 various combinations of sisomicin, amikacin, gentamicin, cefotaxime, doxycycline, trimethoprim and nitroxaline was studied by the chess board method with respect to 25 strains of Brucella melitensis. The synergistic effect with respect to the majority of the cultures was observed with the use of the combinations of gentamicin, amikacin or sisomicin with doxycycline. The combinations of the aminoglycosides with cefotaxime and sisomicin or gentamicin with rifampicin had a summation effect on the majority of the cultures.

[Sensitivity of Brucella melitensis to various antibiotics, drug preparations and their combinations].

In vitro activity of 13 antibiotics and drug preparations as well as some of their combinations was studied with respect to Brucella melitensis. It was shown that the strains of B. melitensis were sensitive to sisomicin, amikacin, gentamicin, cefotaxime, rifaprim +, nitroxoline and trimethoprim.